# Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers

> **NCT01949194** · PHASE2 · UNKNOWN · sponsor: **Gerald Batist** · enrollment: 48 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT01949194
- **Lead sponsor:** Gerald Batist
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-09
- **Primary completion:** 2018-10
- **Final completion:** 2018-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-08-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01949194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01949194, "Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01949194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*